Psy62 - Direct Cost Offsets Related to Belimumab Subcutaneous Administration in Patients With Systemic Lupus Erythematosus in Spain

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2638
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Belimumab in Systemic Lupus Erythematosus

RMD Open
RheumatologyAllergyImmunology
2015English

SAT0231 Safety of Subcutaneous Belimumab in Patients With Systemic Lupus Erythematosus: A 6-Month Open-Label Extension Study

2017English

Belimumab in Systemic Lupus Erythematosus: An Update for Clinicians

Therapeutic Advances in Chronic Disease
Medicine
2011English

Experience of Long-Term Belimumab Use in Patients With Systemic Lupus Erythematosus (A Case Report)

Modern Rheumatology Journal
2013English

Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus

Arthritis Care and Research
Rheumatology
2017English

Tuberculosis in Patients With Systemic Lupus Erythematosus.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1982English

Bone Health in Patients With Systemic Lupus Erythematosus

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2019English

Retinal Disease in Patients With Systemic Lupus Erythematosus

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2000English

Liver Dysfunction in Patients With Systemic Lupus Erythematosus

Internal Medicine
Internal MedicineMedicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy